10x Genomics, Inc. (NASDAQ: TXG) is a Healthcare company (Biotechnology) with a market capitalization of $6.8B. The Maz Rating grades it against the other companies in its sector.
10x Genomics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $56.13, 10x Genomics, Inc. trades at 10.8x sales and 8.6x book value, with an EV/EBITDA of 139.5. Over the last twelve months it generated about $631M of revenue and a net loss of $64M. It runs a gross margin of 71.9%, an operating margin of -11.7% and a net margin of -10.8%. It shows return on equity of -8.2%, return on invested capital of -7.7% and a free cash flow yield of 1.4%. On the balance sheet: a debt-to-equity ratio of 0.09 and a current ratio of 5.12. Over the past 52 weeks the share price ranged from $15.18 to $102.81, with a beta of 2.03.
10x Genomics, Inc. does not currently pay a dividend.
22 Wall Street analyst ratings cover the stock: 10 Buy, 11 Hold and 1 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.